Histone deacetylase (HDAC) inhibitors are emerging as an exciting new class of potential
anticancer agents for the treatment of solid and hematological malignancies. In recent years,
an increasing number of structurally diverse HDAC inhibitors have been identified that
inhibit proliferation and induce differentiation and/or apoptosis of tumor cells in culture and
in animal models. HDAC inhibition causes acetylated nuclear histones to accumulate in both
tumor and normal tissues, providing a surrogate marker for the biological activity of HDAC …